Combined vaccines against angiotensin II receptor type 1 and alpha 1D-adrenergic receptor for hypertension.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
11 Mar 2024
11 Mar 2024
Historique:
medline:
1
5
2024
pubmed:
1
5
2024
entrez:
1
5
2024
Statut:
aheadofprint
Résumé
Compared with monotherapy, combination therapy with multiple antihypertensive drugs has demonstrated superior efficacy in the management of hypertension. The aim of this study was to explore the efficacy of multitarget combined vaccines in achieving simultaneous antihypertensive and target organ protection effects. Our team has developed ATRQβ-001 and ADRQβ-004 vaccines targeting Ang II type 1 receptor (AT1R) and α1D-adrenergic receptor (α1D-AR), respectively. In NG-nitroarginine methyl ester (l-NAME) + abilities spontaneously hypertensive rats (SHRs) model, SHRs were simultaneously inoculated with ATRQβ-001 and ADRQβ-004 vaccines. Histological and biochemical analyses were performed to evaluate the antihypertensive effects and target organ protection of the ATRQβ-001 and ADRQβ-004 combined vaccines in comparison with those of the single vaccine. Both ATRQβ-001 and ADRQβ-004 vaccines induced robust antibody production, resulting in persistent high antibody titers in rats. Notably, the combined administration of both vaccines significantly decreased SBP in SHRs compared with treatment with a single vaccine, both before and after l-NAME administration. Furthermore, the combined vaccine regimen demonstrated superior efficacy in protecting against vascular remodeling, myocardial hypertrophy and fibrosis, and kidney injury in SHRs. Mechanistically, the combined vaccines exhibited significantly downregulated the expression of angiotensin II type 1 receptor (AT1R) and α1D-adrenergic receptor (α1D-AR). Importantly, no apparent immune-related adverse effects were observed in animals immunized with the combined vaccines. Preliminary findings from this investigation suggest that co-administration of the novel ATRQβ-001 and ADRQβ-004 vaccines holds potential as a groundbreaking therapeutic strategy for managing hypertension.Graphical abstract: http://links.lww.com/HJH/C436.
Identifiants
pubmed: 38690916
doi: 10.1097/HJH.0000000000003710
pii: 00004872-990000000-00431
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Carey RM, Moran AE, Whelton PK. Treatment of hypertension: a review. JAMA 2022; 328:1849–1861.
Keuneke C, Yacullo R, Metzger R, Hellmann T, Peters J, Ganten D. The role of tissue renin-angiotensin systems in hypertension and effects of chronic converting-enzyme inhibition. Eur Heart J 1990; 11: (Suppl D): 11–16.
Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34 (4 pt 2):724–728.
Schutte AE, Jafar TH, Poulter NR, Damasceno A, Khan NA, Nilsson PM, et al. Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension. Cardiovasc Res 2023; 119:381–409.
Kawai T, Forrester SJ, O’Brien S, Baggett A, Rizzo V, Eguchi S. AT1 receptor signaling pathways in the cardiovascular system. Pharmacol Res 2017; 125 (Pt a):4–13.
Akinaga J, García-Sáinz JA, Pupo SA. Updates in the function and regulation of (1 -adrenoceptors. Br J Pharmacol 2019; 176:2343–2357.
Tanoue A, Nasa Y, Koshimizu T, Shinoura H, Oshikawa S, Kawai T, et al. The alpha(1D)-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J Clin Invest 2002; 109:765–775.
Gisbert R, Ziani K, Miquel R, Noguera MA, Ivorra MD, Anselmi E, et al. Pathological role of a constitutively active population of alpha(1D)-adrenoceptors in arteries of spontaneously hypertensive rats. Br J Pharmacol 2002; 135:206–216.
Methven L, Simpson PC, McGrath JC. Alpha1A/B-knockout mice explain the native alpha1D-adrenoceptor's role in vasoconstriction and show that its location is independent of the other alpha1-subtypes. Br J Pharmacol 2009; 158:1663–1675.
Oliver E, Martí D, Montó F, Flacco N, Moreno L, Barettino D, et al. The impact of alpha1-adrenoceptors up-regulation accompanied by the impairment of beta-adrenergic vasodilatation in hypertension. J Pharmacol Exp Ther 2009; 328:982–990.
Hosoda C, Koshimizu T-A, Tanoue A, Nasa Y, Oikawa R, Tomabechi T, et al. Two alpha1-adrenergic receptor subtypes regulating the vasopressor response have differential roles in blood pressure regulation. Mol Pharmacol 2005; 67:912–922.
Tanoue A, Koba M, Miyawaki S, Koshimizu TA, Hosoda C, Oshikawa S, Tsujimoto G. Role of the alpha1D-adrenergic receptor in the development of salt-induced hypertension. Hypertension 2002; 40:101–106.
Li C, Yan X, Wu D, Zhang K, Liang X, Pan Y, et al. Vaccine targeted alpha 1D-adrenergic receptor for hypertension. Hypertension 2019; 74:1551–1562.
Chen X, Qiu Z, Yang S, Ding D, Chen F, Zhou Y, et al. Effectiveness and safety of a therapeutic vaccine against angiotensin II receptor type 1 in hypertensive animals. Hypertension 2013; 61:408–416.
Bachmann MF, Dyer MR. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov 2004; 3:81–88.
Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008; 371:821–827.
Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet 2015; 386:801–812.
Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012; 33:829–837.
Ahmad A, Dempsey SK, Daneva Z, Azam M, Li N, Li P-L, et al. Role of nitric oxide in the cardiovascular and renal systems. Int J Mol Sci 2018; 19:2605.
Perez DM. Structure-function of alpha1-adrenergic receptors. Biochem Pharmacol 2007; 73:1051–1062.
Wheatley M, Wootten D, Conner MT, Simms J, Kendrick R, Logan RT, et al. Lifting the lid on GPCRs: the role of extracellular loops. Br J Pharmacol 2012; 165:1688–1703.
Li C, Gubbins PO, Chen GJ. Prior pneumococcal and influenza vaccinations and in-hospital outcomes for community-acquired pneumonia in elderly veterans. J Hosp Med 2015; 10:287–293.
Gilchrist SAN, Nanni A, Levine O. Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers. Am J Public Health 2012; 102:596–605.
Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999; 17: (Suppl 1): S91–S93.
Christenson B, Pauksen K, Sylvan SPE. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. Virol J 2008; 5:52.
Domínguez A, Castilla J, Godoy P, Delgado-Rodríguez M, Saez M, Soldevila N, et al. CIBERESP Cases and Controls in Pandemic Influenza Working Group (Spain) Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons. Hum Vaccin Immunother 2013; 9:865–873.
Conde E, Bertrand R, Balbino B, Bonnefoy J, Stackowicz J, Caillot N, et al. Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice. Nat Commun 2021; 12:2574.
Wang Z, Zeng C, Villar VAM, Chen S-Y, Konkalmatt P, Wang X, et al. Human GRK4 (142 V variant promotes angiotensin II type I receptor-mediated hypertension via renal histone deacetylase type 1 inhibition. Hypertension 2016; 67:325–334.
Zhao X, Zhang Y, Leander M, Li L, Wang G, Emmett N. Altered expression profile of renal ((1D)-adrenergic receptor in diabetes and its modulation by PPAR agonists. J Diabetes Res 2014; 2014:725634.
Kang HM, Ahn SH, Choi P, Ko Y-A, Han SH, Chinga F, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med 2015; 21:37–46.
Tran MT, Zsengeller ZK, Berg AH, Khankin EV, Bhasin MK, Kim W, et al. PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature 2016; 531:528–532.
Johnston CI. Effect of antihypertensive drugs on the renin-angiotensin system. Drugs 1976; 12:274–291.
Taddei S, Virdis A, Mattei P, Duranti P, Favilla S, Salvetti A. Vascular renin-angiotensin system and sympathetic nervous system activity in human hypertension. J Cardiovasc Pharmacol 1994; 23: (Suppl 1): S9–S14.
Wei X, Jin J, Wu J, He Y, Guo J, Yang Z, et al. Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway. Cardiovasc Res 2023; 119:1842–1855.
Brown MJ. Success and failure of vaccines against renin-angiotensin system components. Nat Rev Cardiol 2009; 6:639–647.
Zhu F, Zhou Z, Liao Y. The renin-angiotensin system and therapeutic vaccines for hypertension. Curr Opin Investig Drugs 2008; 9:286–294.
Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007; 25:63–72.
Wu H, Wang Y, Wang G, Qiu Z, Hu X, Zhang H, et al. A bivalent antihypertensive vaccine targeting L-type calcium channels and angiotensin AT1 receptors. Br J Pharmacol 2020; 177:402–419.
Ke F, Kuang W, Hu X, Li C, Ma W, Shi D, et al. A novel vaccine targeting (1-adrenergic receptor. Hypertens Res 2023; 46:1582–1595.
Dai Y, Chen X, Song X, Chen X, Ma W, Lin J, et al. Immunotherapy of endothelin-1 receptor type A for pulmonary arterial hypertension. J Am Coll Cardiol 2019; 73:2567–2580.
Wu D, Pan Y, Yang S, Li C, Zhou Y, Wang Y, et al. PCSK9Qβ-003 vaccine attenuates atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Drugs Ther 2021; 35:141–151.
Wu D, Zhou Y, Pan Y, Li C, Wang Y, Chen F, et al. Vaccine against PCSK9 improved renal fibrosis by regulating fatty acid (-oxidation. J Am Heart Assoc 2020; 9:e014358.
Ding D, Du Y, Qiu Z, Yan S, Chen F, Wang M, et al. Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy. J Mol Med (Berl) 2016; 94:207–218.
Zhou Y, Wang S, Qiu Z, Song X, Pan Y, Hu X, et al. ATRQβ-001 vaccine prevents atherosclerosis in apolipoprotein E-null mice. J Hypertens 2016; 34:474–485.
Zhang H, Liao M, Cao M, Qiu Z, Yan X, Zhou Y, et al. ATRQβ-001 Vaccine prevents experimental abdominal aortic aneurysms. J Am Heart Assoc 2019; 8:e012341.